Houston brain health co. secures $6.5M for rare disease study (opens original article in a new tab)

Houston-based Goldenrod Therapeutics secured $6.5 million in seed funding to advance its drug 11h for treating Friedreich’s ataxia and other neurological conditions.

• Houston-based Goldenrod Therapeutics secured $6.5 million in seed funding to advance its drug 11h for treating Friedreich’s ataxia.
• 11h is a PDE4 inhibitor designed to address brain inflammation with potential applications for multiple neurological and inflammatory conditions.
• The funding will support manufacturing, formulation optimization, and Phase I studies for 11h, which was developed at the University of Nebraska Medical Center.